Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Caphosol is a supersaturated calcium phosphate oral rinse designed to prevent and treat oral mucositis, a common and painful complication of intensive cancer therapies such as high-dose chemotherapy and radiotherapy. The product is supplied as two separate aqueous solutions: Solution A (containing phosphate ions) and Solution B (containing calcium ions). When mixed immediately before use, they form a supersaturated solution that mimics the mineral composition of natural human saliva. This formulation works by moistening and lubricating the oral cavity, maintaining the integrity of the oral mucosal epithelium, and providing high concentrations of calcium and phosphate ions that facilitate the repair of damaged tissues. It is frequently utilized in patients undergoing hematopoietic stem cell transplantation or treatment for head and neck cancers.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on supersaturated calcium phosphate solution.